CYLD deubiquitinates NEMO

Stable Identifier
R-HSA-741411
Type
Reaction [transition]
Species
Homo sapiens
Compartment
cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
CYLD deubiquitinates NEMO
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
RIP2-induced ubiquitination of NEMO and consequent NFkappaB activation can be reversed in a dose-responsive manner by the deubiquitinase CYLD, suggesting that CYLD negatively regulates RIP2-induced NEMO ubiquitinylation.
Literature References
PubMed ID Title Journal Year
12917691 The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination

Cantarella, G, Wallach, D, Courtois, G, Chable-Bessia, C, Israel, A, Kovalenko, A

Nature 2003
15620648 The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO

Asara, JM, Cantley, LC, Wilkins, A, Abbott, DW

Curr Biol 2004
Participants
Input
Output
Participates
as an event of
Catalyst Activity

Lys63-specific deubiquitinase activity of CYLD [cytosol]

Physical Entity
CYLD [cytosol] (Homo sapiens)
Activity
Lys63-specific deubiquitinase activity (GO:0061578)
Orthologous Events
CYLD deubiquitinates NEMO (Bos taurus)
CYLD deubiquitinates NEMO (Canis familiaris)
CYLD deubiquitinates NEMO (Danio rerio)
CYLD deubiquitinates NEMO (Mus musculus)
CYLD deubiquitinates NEMO (Rattus norvegicus)
Authored
Jupe, S  (2010-04-22)
Reviewed
Kufer, TA  (2011-04-28)
Rittinger, K  (2011-06-06)
Wong, E  (2011-06-06)
Created
Jupe, S  (2010-05-14)
Cite Us!